During the past decade, Hospital Universitario Miguel Servet conducted 274 clinical trials. In the 10-year time frame, 274 clinical trials started and 84 clinical trials were completed, i.e. on average, 30.7% percent of trials that started reached the finish line to date. In the past 5 years, 126 clinical trials started and 59 clinical trials were completed. i.e. 46.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hospital Universitario Miguel Servet" #1 sponsor was "Spanish Breast Cancer Research Group" with 25 trials, followed by "Celgene" with 16 trials sponsored, "Pfizer" with 16 trials sponsored, "Grupo Espanol de Investigacion en Sarcomas" with 13 trials sponsored and "Hoffmann-La Roche" with 13 trials sponsored. Other sponsors include 329 different institutions and companies that sponsored additional 198 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hospital Universitario Miguel Servet" #1 collaborator was "Hoffmann-La Roche" with 13 trials as a collaborator, "Pfizer" with 12 trials as a collaborator, "Hospital Miguel Servet" with 9 trials as a collaborator, "Apices Soluciones S.L." with 6 trials as a collaborator and "AstraZeneca" with 6 trials as a collaborator. Other collaborators include 348 different institutions and companies that were collaborators in the rest 283 trials.

According to Clinical.Site data, the most researched conditions in "Hospital Universitario Miguel Servet" are "Breast Cancer" (29 trials), "Crohn Disease" (10 trials), "Multiple Myeloma" (10 trials), "Metastatic Breast Cancer" (8 trials) and "Breast Neoplasms" (7 trials). Many other conditions were trialed in "Hospital Universitario Miguel Servet" in a lesser frequency.

Most popular intervention types in "Hospital Universitario Miguel Servet" are "Drug" (299 trials), "Other" (48 trials), "Procedure" (25 trials), "Device" (24 trials) and "Biological" (19 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (55 trials), "Capecitabine" (13 trials), "Paclitaxel" (13 trials), "Gemcitabine" (12 trials) and "Carboplatin" (10 trials). Other intervention names were less common.

The vast majority of trials in "Hospital Universitario Miguel Servet" are 353 trials for "All" genders, 54 trials for "Female" genders and 10 trials for "Male" genders.

Currently, there are 143 active trials in "Hospital Universitario Miguel Servet". 3 are not yet recruiting, 78 are recruiting, 61 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 217 completed trials in Hospital Universitario Miguel Servet, undefined suspended trials, and 35 terminated clinical trials to date.

Out of the total trials that were conducted in Hospital Universitario Miguel Servet, 21 "Phase 1" clinical trials were conducted, 118 "Phase 2" clinical trials and 151 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 29 trials, and there were also 24 trials that are defined as “Not Applicable".